Clinical trials: Advanced Solid Cancer
Neoplasms, Pancreatic
First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors
In an unbiased CRISPR screen, RIPK1 was identified as a top gene contributing to immunotherapy resistance. In addition, RIPK1 has been reported to drive pancreatic oncogenesis.
- Trial name
- NCT03681951
- Testing
- GSK3145095, Pembrolizumab
- Where
- 6 sites in United States
- Volunteers
- 8 people
- Sponsor
- GlaxoSmithKline
Neoplasms
A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors
To assess the safety and tolerability at increasing dose levels of PF-06647020 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
- Trial name
- NCT02222922
- Testing
- PF-06647020 Q3W, fluconazole, PF-06647020 Q2W
- Where
- 17 sites in United States, Spain
- Volunteers
- 138 people
- Sponsor
- Pfizer
Ovarian Cancer, Solid Tumors
A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors
The main aim of this study are to check for side effects from TAK-853, check how much TAK-853 participants can receive without getting side effects from it, check how well TAK-853 controls symptoms, and to check how much TAK-853…
- Trial name
- NCT06390995
- Testing
- TAK-853
- Where
- 20 sites in Japan
- Volunteers
- 28 people
- Sponsor
- Takeda
Solid Tumor, Adult
Study of ASTX029 in Subjects With Advanced Solid Tumors
This study is a first-in-human, open-label, multicenter, Phase 1-2 study to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of ASTX029 administered orally to participants with advanced…
- Trial name
- NCT03520075
- Testing
- ASTX029
- Where
- 31 sites in United States, France and 2 more
- Volunteers
- 192 people
- Sponsor
- Taiho Oncology, Inc.
Solid Tumor
Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors
The purpose of this study is to determine whether the combination of Ulocuplumab and Nivolumab is safe and effective in the treatment of pancreatic cancer and small cell lung cancer.
- Trial name
- CXCessoR4 (NCT02472977)
- Testing
- Ulocuplumab, Nivolumab
- Where
- 7 sites in United States, Finland
- Volunteers
- 61 people
- Sponsor
- Bristol-Myers Squibb
Solid Tumors, KRAS Mutation
A Study to Test Different Doses of BI 3011441 in Japanese People With Different Types of Advanced Cancer (NRAS/KRAS Mutation Positive)
This study is open to Japanese adults with different types of advanced cancer that are positive for NRAS/KRAS mutations. This is a study in people for whom previous treatment was not successful or no standard treatment exists.
- Trial name
- NCT04742556
- Testing
- BI 3011441
- Where
- 3 sites in Japan
- Volunteers
- 15 people
- Sponsor
- Boehringer Ingelheim
Head and Neck Squamous Cell Carcinoma, Breast Cancer
A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers
This is an open-label, multicenter, Phase 1/2 study of the CTLA-4 antibody, tremelimumab, and the PD-L1 antibody, durvalumab (MEDI4736), in combination with the tumor microenvironment (TME) modulator poly-ICLC, a TLR3 agonist, in…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Breast Cancer, Sarcoma, Merkel Cell Carcinoma
- Trial name
- NCT02643303
- Testing
- Durvalumab, Tremelimumab, Poly-ICLC
- Where
- 7 sites in United States
- Volunteers
- 58 people
- Sponsor
- Ludwig Institute for Cancer Research
Solid Tumor, Adult
Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors
A single arm phase II study with 30 patients of leronlimab (PRO 140) in patients with CCR5+ locally advanced or metastatic solid tumors.
- Trial name
- NCT04504942
- Testing
- Leronlimab
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- CytoDyn, Inc.
Ovary Cancer, Cervix Cancer
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
The purpose of the trial is to establish the tolerability of HuMax-TF-ADC in a mixed population of patients with specified solid tumors.
- Conditions
- Ovary Cancer, Cervix Cancer, Endometrium Cancer, Bladder Cancer
- Trial name
- NCT02001623
- Testing
- Tisotumab Vedotin (HuMax-TF-ADC)
- Where
- 29 sites in United States, Belgium and 3 more
- Volunteers
- 195 people
- Sponsor
- Seagen Inc.
Advanced Solid Tumor
XTX202 in Patients With Advanced Solid Tumors
A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of XTX202 in Patients with Advanced Solid Tumors
- Trial name
- NCT05052268
- Testing
- XTX202
- Where
- 15 sites in United States
- Volunteers
- 95 people
- Sponsor
- Xilio Development, Inc.
Advanced or Metastatic Solid Tumors, Microsatellite Instability Low
A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors
This is an open-label, non-randomized, Phase 1b/2 study to determine the safety and tolerability of NC410 when combined with a standard dose of pembrolizumab.
- Conditions
- Advanced or Metastatic Solid Tumors, Microsatellite Instability Low, Microsatellite Instability High, Microsatellite Stable
- Trial name
- NCT05572684
- Testing
- NC410, pembrolizumab
- Where
- 17 sites in United States
- Volunteers
- 97 people
- Sponsor
- NextCure, Inc.
Neoplasms
A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours
The main objective of the dose-escalation part of the trial is to determine the safety and tolerability, and to determine the Maximum Tolerated Dose and/or the Recommended Phase 2 Dose (RP2D) of BI 754091 on the basis of patients…
- Trial name
- NCT02952248
- Testing
- BI 754091
- Where
- 13 sites in United States, Canada and 1 more
- Volunteers
- 110 people
- Sponsor
- Boehringer Ingelheim
Nasopharyngeal Carcinoma, EBV-Related Gastric Carcinoma
Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPC
This study will evaluate the safety and efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive solid tumors and in combination with pembrolizumab in patients with…
- Conditions
- Nasopharyngeal Carcinoma, EBV-Related Gastric Carcinoma, EBV-Related Leiomyosarcoma, EBV Related Carcinoma
- Trial name
- NCT05166577
- Testing
- Nanatinostat, Valganciclovir, Pembrolizumab
- Where
- 13 sites in United States, Australia and 6 more
- Volunteers
- 26 people
- Sponsor
- Viracta Therapeutics, Inc.
Adenocarcinoma of the Pancreas, Advanced Solid Tumors
QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas
AMG 479 is an investigational fully human monoclonal antibody that targets type 1 insulin-like growth factor receptor (IGF-1R). Signaling through IGF-1R plays an important role in the regulation of cell growth and survival.
- Conditions
- Adenocarcinoma of the Pancreas, Advanced Solid Tumors, Cancer, Cancer of Pancreas
- Trial name
- GAMMA (NCT01231347)
- Testing
- AMG 479, gemcitabine
- Where
- 152 sites in United States, Australia and 30 more
- Volunteers
- 800 people
- Sponsor
- NantCell, Inc.
Neoplasms
Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors
This trial will evaluate the safety and efficacy of first time in human engineered T-cell therapies, in participants with advanced tumors.
- Trial name
- NCT04526509
- Testing
- GSK3901961, GSK3845097, GSK4427296
- Where
- 17 sites in United States, Australia and 4 more
- Volunteers
- 12 people
- Sponsor
- Adaptimmune
Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm
Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors
This phase I trial identifies the best dose, possible benefits and/or side effects of gemcitabine in combination with elimusertib (BAY 1895344) in treating patients with pancreatic, ovarian, and other solid tumors that have…
- Conditions
- Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Pancreatic Adenocarcinoma
- Trial name
- NCT04616534
- Testing
- Biopsy Procedure, Biospecimen Collection, Diagnostic Imaging Testing
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumors
A Study to Evaluate the Effect of Itraconazole and Rifampin on the Pharmacokinetics of Talazoparib in Patients With Advanced Solid Tumors
This is a study in patients with advanced solid tumors for the investigation of P-gp inhibition and induction on the PK of talazoparib.
- Trial name
- NCT03077607
- Testing
- Talazoparib, Itraconazole, Rifampin
- Where
- 7 sites in Hungary, Moldova and 2 more
- Volunteers
- 36 people
- Sponsor
- Pfizer
Cancer
Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or Metastatic Solid Tumors
This is a dose escalation safety study of birinapant (TL32711) in combination with chemotherapy in subjects with advanced or metastatic solid tumors.
- Trial name
- NCT01188499
- Testing
- Birinapant
- Where
- 7 sites in United States
- Volunteers
- 176 people
- Sponsor
- TetraLogic Pharmaceuticals
Advanced Solid Tumor, Metastatic Solid Tumor
Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors
This is an open-label, multicenter, phase 2 study of lurbinectedin monotherapy in participants with advanced (metastatic and/or unresectable) solid tumors.
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Urothelial Cancer, Poorly Differentiated Neuroendocrine Carcinomas
- Trial name
- JAZZ EMERGE201 (NCT05126433)
- Testing
- Lurbinectedin
- Where
- 17 sites in United States
- Volunteers
- 47 people
- Sponsor
- Jazz Pharmaceuticals
Advanced Malignancies, Metastatic Cancer
A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors
The purpose of this study is to determine the safety and tolerability and assess preliminary efficacy of INCAGN01949 in subjects with advanced or metastatic solid tumors.
- Trial name
- NCT02923349
- Testing
- INCAGN01949
- Where
- 8 sites in United States, Spain and 2 more
- Volunteers
- 87 people
- Sponsor
- Incyte Biosciences International Sàrl